


Please note: This graphic shows the status of current and anticipated policy implementation work. Items above the date line show policies where implementation is in progress or on hold, and items below the date line show estimates for policy activities where implementation has not yet been directed by the Board.



Key					
Current Implementation in Progress		Implementation on Hold		Board Consideration/Adoption	
Estimated Contracted Party Implementation		Public Comment Period		Preparation for Board Consideration	
Policy Development Process Completed		Operational Design Phase		Finalize Policy	
Estimated Policy Implementation (if adopted)		Internal Project Organization		Continues past 2024	

¹Please note this policy implementation was split into two tracks - one for IGO identifiers and one for INGO identifiers. The IGO identifiers implementation was considered complete as of 1 August 2020. The INGO implementation is currently on hold. [Click here](#) to learn more.

²EPDP Phase 2 ODP for SSAD Recs 1-18 only. Please note on [27 April 2022](#) the GNSO Council requested that the Board pause consideration, to which the Board [agreed](#).

³The Board has [paused](#) its consideration of the SSAD policy recommendations while the SSAD Light design work is further explored. On 17 November 2022, the GNSO Council published a [letter](#) to the Board noting that they accept the WHOIS Disclosure System paper and requested the Board to proceed with implementation of the WHOIS Disclosure System.

⁴EPDP Phase 2 Priority 2 Recs are included with the EPDP Phase 1 Implementation public comment period

⁵Please note IGO-INGO Access to Curative Rights Protection Mechanisms was split into three tracks - INGO Claims System Specification, Protection of Red Cross & Red Crescent Identifiers and Protection of "Reserved Names". [Click here](#) for more info on the status of each track.

⁶The EPDP on Specific Curative Rights Protections for IGOs was initiated by the GNSO Council to consider whether an appropriate policy solution can be developed that is generally consistent with Recommendations 1–4 of the IGO-INGO Access to Curative Rights [Final Report](#), and allows for the possibility that an IGO may have jurisdictional immunity in cases where a registrant that has lost a UDRP or URS. Learn more [here](#).